557 related articles for article (PubMed ID: 9085323)
1. Lansoprazole: a comprehensive review.
Zimmermann AE; Katona BG
Pharmacotherapy; 1997; 17(2):308-26. PubMed ID: 9085323
[TBL] [Abstract][Full Text] [Related]
2. Progress with proton pump inhibitors in acid peptic disease: treatment of duodenal and gastric ulcer.
Florent C
Clin Ther; 1993; 15 Suppl B():14-21. PubMed ID: 7911399
[TBL] [Abstract][Full Text] [Related]
3. Proton pump inhibitors and acid-related diseases.
Sachs G
Pharmacotherapy; 1997; 17(1):22-37. PubMed ID: 9017763
[TBL] [Abstract][Full Text] [Related]
4. Treatment of patients with Zollinger-Ellison syndrome.
Mignon M; Pospai D; Forestier S; Vatier J; Vallot T
Clin Ther; 1993; 15 Suppl B():22-31. PubMed ID: 8205592
[TBL] [Abstract][Full Text] [Related]
5. Lansoprazole: pharmacokinetics, pharmacodynamics and clinical uses.
Gremse DA
Expert Opin Pharmacother; 2001 Oct; 2(10):1663-70. PubMed ID: 11825309
[TBL] [Abstract][Full Text] [Related]
6. Lansoprazole. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy in acid-related disorders.
Spencer CM; Faulds D
Drugs; 1994 Sep; 48(3):404-30. PubMed ID: 7527761
[TBL] [Abstract][Full Text] [Related]
7. Impact of Helicobacter pylori eradication on the anti-secretory efficacy of lansoprazole in gastroesophageal reflux disease patients.
Giral A; Celikel CA; Ozdogan O; Tözün N; Ulusoy NB; Kalayci C
J Gastroenterol Hepatol; 2005 Dec; 20(12):1886-91. PubMed ID: 16336449
[TBL] [Abstract][Full Text] [Related]
8. Meta-analysis of randomized clinical trials comparing lansoprazole with ranitidine or famotidine in the treatment of acute duodenal ulcer.
Poynard T; Lemaire M; Agostini H
Eur J Gastroenterol Hepatol; 1995 Jul; 7(7):661-5. PubMed ID: 8590162
[TBL] [Abstract][Full Text] [Related]
9. Lansoprazole. An update of its pharmacological properties and clinical efficacy in the management of acid-related disorders.
Langtry HD; Wilde MI
Drugs; 1997 Sep; 54(3):473-500. PubMed ID: 9279507
[TBL] [Abstract][Full Text] [Related]
10. [Lansoprazol ++ : a new proton pump inhibitor].
Baczek J; Laskowiec G
Pol Merkur Lekarski; 1998 Jun; 4(24):339-41. PubMed ID: 9771021
[TBL] [Abstract][Full Text] [Related]
11. Lansoprazole. A review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy in acid-related disorders.
Barradell LB; Faulds D; McTavish D
Drugs; 1992 Aug; 44(2):225-50. PubMed ID: 1382017
[TBL] [Abstract][Full Text] [Related]
12. Rabeprazole: a review of its use in acid-related gastrointestinal disorders.
Langtry HD; Markham A
Drugs; 1999 Oct; 58(4):725-42. PubMed ID: 10551440
[TBL] [Abstract][Full Text] [Related]
13. Lansoprazole and omeprazole in the treatment of acid peptic disorders.
Blum RA
Am J Health Syst Pharm; 1996 Jun; 53(12):1401-15. PubMed ID: 8781686
[TBL] [Abstract][Full Text] [Related]
14. Usefulness of proton pump inhibitor (PPI) maintenance therapy for patients with H. pylori-negative recurrent peptic ulcer after eradication therapy for H. pylori: pathophysiological characteristics of H. pylori-negative recurrent ulcer scars and beyond acid suppression by PPI.
Ohara T; Morishita T; Suzuki H; Masaoka T; Ishii H
Hepatogastroenterology; 2004; 51(56):338-42. PubMed ID: 15086153
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of lansoprazole in the treatment of erosive reflux esophagitis. The Lansoprazole Group.
Castell DO; Richter JE; Robinson M; Sontag SJ; Haber MM
Am J Gastroenterol; 1996 Sep; 91(9):1749-57. PubMed ID: 8792693
[TBL] [Abstract][Full Text] [Related]
16. pH, healing rate, and symptom relief in patients with GERD.
Huang JQ; Hunt RH
Yale J Biol Med; 1999; 72(2-3):181-94. PubMed ID: 10780580
[TBL] [Abstract][Full Text] [Related]
17. An overview of the pharmacology, efficacy, safety and cost-effectiveness of lansoprazole.
Bown RL
Int J Clin Pract; 2002 Mar; 56(2):132-9. PubMed ID: 11926700
[TBL] [Abstract][Full Text] [Related]
18. [Comparative effect of lansoprazole/amoxicillin with omeprazole/amoxicillin for the eradication of Helicobacter pylori in patients with duodenal ulcer].
Kayser S; Flury R; Zbinden R; Fried M; Wirth HP
Schweiz Med Wochenschr; 1997 Apr; 127(17):722-7. PubMed ID: 9221483
[TBL] [Abstract][Full Text] [Related]
19. Treatment of reflux esophagitis resistant to H2-receptor antagonists with lansoprazole, a new H+/K(+)-ATPase inhibitor: a controlled, double-blind study. Lansoprazole Study Group.
Feldman M; Harford WV; Fisher RS; Sampliner RE; Murray SB; Greski-Rose PA; Jennings DE
Am J Gastroenterol; 1993 Aug; 88(8):1212-7. PubMed ID: 8101695
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological and pharmacodynamic essentials of H(2)-receptor antagonists and proton pump inhibitors for the practising physician.
Huang JQ; Hunt RH
Best Pract Res Clin Gastroenterol; 2001 Jun; 15(3):355-70. PubMed ID: 11403532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
